GenoMed CEO Says Last Night’s Bill Will Bankrupt US Healthcare Sooner


David W. Moskowitz MD
CEO, GenoMed
Tel. 314-983-9933

March 22, 2010—GenoMed®, the Public Health Company™, announced that last night’s healthcare bill, passed along party lines but with bipartisan opposition, will only hasten the bankruptcy of the American healthcare system. The bill does nothing significant to lower costs, which everyone agrees are skyrocketing.

Dr. David Moskowitz, GenoMed’s CEO, said, “President Obama can’t even get the CEO’s of America’s health insurance plans to tell him their profit margin. How does he expect to keep them from raising premiums?”

Dr. Moskowitz continued, “Relying on the health insurance companies to deliver healthcare to the nation’s 50 million uninsured is a terrible way to control costs. It would have been much better to use the Public Health Service, a strong public option, which the President can control.”

Dr. Moskowitz ended by saying, “Telling the health insurance companies how to run their business won’t work. I can see the response right now: ‘OK, we’ll cover pre-existing conditions, but it’ll cost you!’ The insurance companies raised their premiums before this bill was even passed. This is a huge government give-away to the health plans, even bigger than the bank bail-out.”

For more, go to

About GenoMed (

GenoMed was founded in 2001 by Dr. David Moskowitz, a kidney specialist. The company uses cutting-edge science, namely medical genomics, to improve clinical outcomes. For years, GenoMed seems to be the only player in global healthcare that’s serious about lowering costs. GenoMed invites like-minded individuals and institutions to contact the company. In particular, GenoMed is working to make the world dialysis-free by 2015.

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.